MD
The startup develops an in vitro diagnostic test that assesses the metastatic risk in early-stage melanoma patients. This enables healthcare providers to tailor treatment plans, improving patient outcomes and overall well-being.
Updated 3 months ago
Funding
$800K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops an in vitro diagnostic test that assesses the metastatic risk in early-stage melanoma patients. This enables healthcare providers to tailor treatment plans, improving patient outcomes and overall well-being.